Clinical trial: Inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects

  title={Clinical trial: Inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects},
  author={Hyung-Keun Kim and Soo-Heon Park and Dae Young Cheung and Young-Seok Cho and Jin-Il Kim and Sung-Soo Kim and Hiun Suk Chae and Jae-Kwang Kim and In Sik Chung},
  journal={Journal of Gastroenterology and Hepatology},
Background and Aim:  Revaprazan is a novel acid pump antagonist. The aim of this study was to investigate the inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects. 

[Effect of acid pump antagonist (Revaprazan, Revanex(R)) on the result of 13C urea breath test in the patients with Helicobacter pylori associated peptic ulcer disease].

  • Seon-Young Park
  • Medicine
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • 2011
Ⓡ Result Breath Helioco-bacter pylori

Pharmacodynamics of tegoprazan and revaprazan after single and multiple oral doses in healthy subjects

Potassium‐competitive acid blockers (P‐CABs) are emerging as novel treatments for acid‐related disorders including gastroesophageal reflux disease and the pharmacodynamics and safety/tolerability of the two drugs have never been compared.

Potent Acid Suppression with PPIs and P-CABs: What’s New?

The needs, individual new drug classes and key individual new treatments into clinical context, including the pharmacology, the unmet clinical needs across the acid-related disorders, the place of new drug treatments, and where superiority exists are reviewed.

The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease.

A new class of antisecretory drugs, developed to overcome many of the drawbacks of PPIs, offer advances in the treatment of GERD including rapid heartburn relief, faster and more reliable healing of severe grades of erosive esophagitis, as a consequence of better control of nighttime acid secretion than PPIs.

Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases

Vonoprazan was recently innovated as a novel, orally active P-CAB, which does not require an acidic environment for activation, has long-term stability at the site of action, and has satisfactory safety and tolerability and may address the unmet medical need for the treatment of acid-related diseases.

Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date

  • K. Sugano
  • Medicine
    Therapeutic advances in gastroenterology
  • 2018
Since the clinical trial data, as well as postmarketed clinical data, have consistently demonstrated superiority of vonoprazan over conventional PPIs in terms of achieving healing of mucosal breaks and maintaining the healing, it may provide an excellent, if not complete, option for fulfilling some of the unmet needs for current GERD therapy.

Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations

Clinical and pharmacological investigations have confirmed a more rapid, potent and prolonged inhibition of acid secretion, including a better nighttime acid control, and a less antisecretory variability, as compared with PPIs.

The Efficacy of Short-term Administration of Revaprazan on Gastroesophageal Reflux Symptoms: Comparison with Half Dose Esomeprazole, a Pilot Study

Revaprazan is not inferior to esomeprazole in therapeutic efficacy for gastroesophageal reflux symptoms and is a safe and useful therapeutic agent to reduce the frequency of gastroesphagealReflux symptoms.

Acid Suppressant Therapy: a Step Forward with Potassium-Competitive Acid Blockers

In the treatment of severe (LA C & D) reflux esophagitis and H. pylori eradication, vonoprazan proved to be superior to PPIs, and other uses of P-CABs are being evaluated, but clinical data are not yet sufficient to allow a definitive answer on its efficacy and possible superiority over the current standard of care.



Time to maximum effect of lansoprazole on gastric pH in normal male volunteers

Background: The time to maximum inhibition of gastric acidity resulting from repeated oral dosing with lansoprazole 30 mg daily for 7 days was studied in nine healthy male volunteers.

Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors

This data indicates that rapid and consistent acid suppression on the first day of dosing may be important in treating acid‐related disorders.

Oral rabeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects

Intravenous pantoprazole is often administered inappropriately to hospitalized patients who can take oral medications, and should not be administered inappropriately, according to the World Health Organization.

A placebo‐controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24‐h intragastric acidity and plasma gastrin concentrations in young healthy male subjects

A single daily 20 mg dose significantly decreases 24‐h intragastric acidity and there are no data currently available directly comparing the effect of rabeprazole on 24-h acidity with established proton pump inhibitors.


Antisecretory activity of SCH 28080 is confirmed in man and this drug or an analogue may have potential in anti‐ulcer therapy.

Ambulatory gastric pH monitoring: proper probe placement and normal values

: Gastric acid production may persist while patients are treated with proton pump inhibitors. Twenty‐four‐hour intragastric pH monitoring is being used to identify gastric acid in the stomach while

Phase III Clinical Trial of Revaprazan (Revanex(R)) for Gastric Ulcer

Revaprazan has similar efficacy to omeprazole in the treatment of patients with gastric ulcer with a once a day application of revapraza 200 mg or omepazole 20 mg over a 4 to 8-week period.

Current status of acid pump antagonists (reversible PPIs).

As was predicted by the above-mentioned dog model, available clinical phase I data confirm dose-dependent pharmacodynamics of BY841 in man and demonstrates lack of tolerance development, the latter being a well-known disadvantage of H2-receptor antagonists.

Phase III Clinical Trial of Revaprazan (Revanex) for Gastritis

The efficacy of revaprazan was higher than that of ranitidine for the estimated improvement rate according to endoscopy and also for the symptomatological improvement rate, and revapazan was well tolerated by the subjects suffering with gastritis.